Business
ASX 200 on watch after study shows Moderna’s COVID-19 vaccine is 94.5% effective // Motley Fool Australia
The S&P/ASX 200 Index (ASX: XJO) could be given a boost today from news that there is now a second potentially effective COVID-19 vaccine.
Overnight, biotechnology company Moderna released an update on its Phase 3 study of mRNA-1273.
What did Moderna announce?
According to the release, the National Institutes of Health-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%.
This study enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID).
The primary endpoint of the…
-
Business23 hours agoForget CBA and buy these high-yield ASX dividend shares
-
Business24 hours agoHere’s a starter portfolio of ASX 200 shares to consider for growth, dividends, and value!
-
Noosa News20 hours agoMan dies after stabbing in inner-city unit
-
Noosa News23 hours agoThe Almond Ashes sees Australia and India mix business and cricket